Techcyte, Inc., an Orem, UT-based deep learning image analysis platform provider, closed a $4.3m funding round.
Backers included investors from previous rounds, employees and strategic partners.
The funds will be used to commercialize its digital pathology platform to veterinary, human and air quality labs in the United States and international markets and to perform the clinical tests required for an FDA 510k.
Led by Ralph Yarro, CEO, and Ben Cahoon, COO, Techcyte uses deep machine learning to perform image analysis of whole slide images. Image analysis is required for widespread adoption of digital pathology in research, pharma, human, air quality and veterinary diagnostic testing.
The company provides a SAAS deep learning digital pathology platform and has been working with labs, doctors and experts around the world to annotate hundreds of thousands of images to feed into the deep learning algorithms.
Over the next few months, the company will launch algorithms to classify blood, ova and parasites, cervical mucus and mold spores.